Veterinary medicines European public assessment report (EPAR): Cytopoint, lokivetmab, Status: Authorised
Veterinary medicines European public assessment report (EPAR): Cytopoint, lokivetmab, Status: Authorised
Veterinary medicines European public assessment report (EPAR): Cytopoint, lokivetmab, Status: Authorised
Human medicines European public assessment report (EPAR): Skilarence, dimethyl fumarate, Date of authorisation: 23/06/2017, Revision: 13, Status: Authorised
European Organisation for Research and Treatment of Cancer (EORTC) bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, 9 April 2025
EMEA-003389-PIP01-23
2024-2026 Work Plan of the Good Clinical Practice Inspectors Working Group (GCP IWG)
EMEA-003300-PIP01-22
EMEA-002951-PIP02-21
Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024
Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0034/2024
Methylphenidate product-specific bioequivelance guidance